Agios Pharmaceuticals, Inc.'s (AGIO) CEO Jacqualyn Fouse on Q1 2020 Results - Earnings Call TranscriptSeeking Alpha • 04/30/20
Agios Pharmaceuticals Shows Improved Relative Strength; Still Shy Of BenchmarkInvestors Business Daily • 04/14/20
Coronavirus Anchor Series: Agios With Strong Cash And 52-Week Low Price Has Good PotentialSeeking Alpha • 04/14/20
Agios Receives Positive Opinion on Orphan Drug Designation from the European Medicines Agency for Mitapivat in Pyruvate Kinase DeficiencyGlobeNewsWire • 03/30/20
Agios Provides Update on 2016 Collaboration Agreement with Celgene, a Wholly Owned Subsidiary of Bristol Myers SquibbGlobeNewsWire • 03/25/20
Agios Announces FDA Clearance of Investigational New Drug Application for AG-946, a Next-Generation PKR ActivatorGlobeNewsWire • 03/23/20
Why Is Agios Pharmaceuticals (AGIO) Down 28.7% Since Last Earnings Report?Zacks Investment Research • 03/14/20
Agios Pharmaceuticals, Inc. (AGIO) CEO Jacqualyn Fouse on Q4 2019 Results - Earnings Call TranscriptSeeking Alpha • 02/13/20
Agios Pharmaceuticals (AGIO) Reports Q4 Loss, Tops Revenue EstimatesZacks Investment Research • 02/13/20
Agios Receives FDA Breakthrough Therapy Designation for TIBSOVO® (ivosidenib) for the Treatment of Adult Patients with Relapsed or Refractory Myelodysplastic Syndrome with an IDH1 MutationGlobeNewsWire • 12/16/19
Agios Presents Updated Data for Mitapivat from Extension Phase of the DRIVE PK Study in Patients with Pyruvate Kinase DeficiencyGlobeNewsWire • 12/09/19
Agios Presents Translational Data to Further Characterize the Role of TIBSOVO® (ivosidenib) Treatment in IDH1 Mutant Acute Myeloid Leukemia (AML)GlobeNewsWire • 12/09/19
Agios Establishes Proof-of-Concept for Mitapivat in Non-transfusion-dependent Thalassemia Based on Preliminary Phase 2 ResultsGlobeNewsWire • 12/08/19
Agios Pharmaceuticals Raised $294 Million to Fight Cancer and Rare Genetic Diseases: What It Means for InvestorsThe Motley Fool • 11/27/19
Agios Presents New Pharmacodynamic and Response Data from Both Cohorts of the Perioperative Study of Vorasidenib and TIBSOVO® (ivosidenib) in Patients with IDH1 Mutant Positive Low-Grade GliomaGlobeNewsWire • 11/22/19
Agios Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional SharesGlobeNewsWire • 11/13/19
Agios to Present Broad Set of Clinical and Translational Data for Oncology and Rare Genetic Disease Programs at the 2019 ASH Annual MeetingGlobeNewsWire • 11/06/19